ESTRO 2021 Abstract Book

S1214

ESTRO 2021

Digital Poster: Other

PO-1482 Harmonizing the nomenclature in a radiotherapy department: a quality improvement project M.D.C. Lopes 1 , T. Ventura 1 , J. Mateus 1 , L. Khouri 2 , T. Serra 2 , F. Alves 1 , P. Alves 2 1 ipocfg, E.P.E., Medical Physics, Coimbra, Portugal; 2 ipocfg, E.P.E., Radiotherapy, Coimbra, Portugal Purpose or Objective The purpose of the quality improvement (QI) project is to harmonize/standardize the nomenclature throughout the radiotherapy treatment process, including image sets, targets (PTV) and organs at risk (OAR) delineations, treatment planning concepts and metrics. The aim of the QI project was that the consensus nomenclature in all treatment steps was accomplished in more than 90% of all entries after the first six The used QI tools included flowcharts, PDCA (plan-do-check-act) consecutive cycles and control charts. The different steps of the project were: 1) Review the radiotherapy workflow and identify the steps where standard nomenclature would apply; 2) Implement standard nomenclature templates in the different software (Velocity AI, TPS, documents in MOSAIQ, etc.) and approve the harmonization guidelines for every step in the global treatment workflow, following international recommendations [1]; 3) Choose one pathology (head and neck (H&N)) for a pilot study; 4) Monitor the progress every three months, report the results and identify the need for improvement/clarification; 5) Extend the project to other pathologies. Results For the global treatment workflow, 11 entries have been identified for which harmonized nomenclature rules have been established. Concerning the pilot study, after the first month, over 35 H&N patients, the nomenclature rules have been accomplished in 78.2% of all entries. 35.3% of the fails concerned the structures' names, 29.4% the name of the dose file exported from the TPS to the Velocity AI system, 23.5% the name of the TC image set and 11.8% the names of courses and/or plans in the MosaiQ. Three months after the beginning of the pilot study, the passing rate raised to 84.5% of all entries. At this stage, no failures occurred concerning structures names. The majority of the fails (52.2%) were detected in the nomenclature of cases/plans either in the TPS or in MosaiQ, The persisting fails in the TC image sets (17.4%) derived from unclear rules concerning metastatic disease. At the end of the pilot study and after the run of some PDCA cycles, the passing rate of accomplishment reached 87%. The extension to other pathologies was included in February 2021. Conclusion The QI project succeeded in its main aim although the quantitative target established for the pilot study has not been reached. It involved all professionals in the radiotherapy department, contributing to enhancing a safety culture and paving the way for future developments as, for instance, the introduction of automated planning in the clinical practice. The harmonization of nomenclature promotes enhancements in safety and quality for patients and professionals both within and between radiotherapy centers for routine ongoing practice. Looking ahead, it enables data pooling for outcomes research, registries, and clinical trials. [1] C. S. Mayo et al, Report AAPM Task Group 263: Standardizing Nomenclatures in Radiation Oncology. 2018 months of the project. Materials and Methods PO-1483 Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey E.S. van Aken 1 , Y.M. van der Linden 2 , C.A. Marijnen 1,2 , J.V. van Thienen 3 , A.J. de Langen 4 , M.C. de Jong 1 1 The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands; 2 Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands; 3 The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Amsterdam, The Netherlands; 4 The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Thoracic Oncology, Amsterdam, The Netherlands Purpose or Objective With the introduction of tyrosine kinase inhibitors and systemic antibodies, including immune checkpoint inhibitors, the overall survival of advanced cancer patients has vastly improved for many tumor types. Although it is unclear whether hypofractionated radiotherapy combined with these drugs is safe, patients are